Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Prohost Letter #458 ~ Obesity

December 18, 2023 0

Prohost Letter #458 ~ Obesity Finally, obesity is being recognized as a severe sickness. Indeed, obesity …

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology

December 13, 2023 0

Editas Medicine and Vertex Pharmaceuticals in the NEWA Today December 13, 2023, Editas Medicine (EDIT) announced …

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

December 13, 2023 0

Vertex Pharmaceuticals in the NEWS Today, December 13, 2023, Vertex Pharmaceuticals (VRTX) announced positive results from …

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

December 11, 2023 0

Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr …

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

December 6, 2023 0

Novartis Approval Novartis (NVS) product Fabhalta (iptacopan) is a Factor B inhibitor that acts in the …

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

December 5, 2023 0

Roche in the NEWS From Basel, today, December 5, 2023 - Roche (RHHBY) announced positive results …

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

December 4, 2023 0

EyePoint Pharmaceuticals Treating Wet Age-Related Macular Degeneration In today's press release, EyePoint Pharmaceuticals (EYPT) announced positive …

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

December 2, 2023 0

Altimmune Positive Topline Results Altimmune (ALT) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity …

AbbVie Inc to Acquire ImmunoGen

November 30, 2023 0

AbbVie Inc Acquisition of Immunogen in the News AbbVie Inc. (ABBV) and ImmunoGen (IMGN) today announced …

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19

November 28, 2023 0

Carlisle Companies Inc and Arcturus Therapeutics in the NEWS Today, November 28, 2023, Global biotechnology leaders …

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

November 28, 2023 0

Immunovant Inc in the NEWS Immunovant, Inc. (IMVT) announced initial data from 600 mg MAD cohort …

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

November 22, 2023 0

Anavex Life Sciences Granted US Patent Anavex Life Sciences (AVXL) – a development-stage biopharmaceutical company announced that the United …

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.

November 17, 2023 0

AbbVie Inc UBRELVY Results Published in The Lancet AbbVie Inc (ABBV) announced detailed results published in The Lancet evaluating …

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

November 16, 2023 0

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of CASGEVY Conditional Approval for Both Sickle Cell Disease …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Prohost Letter #458 ~ Obesity

Editas Medicine and Vertex Pharmaceuticals: Non-Exclusive License Agreement in Cas9 Gene Editing Technology

Vertex Stock Soars Pre-Market Announcing Positive Results from Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Roche Announces Positive Phase III Results for Inavolisib Combination in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation

EyePoint Pharmaceuticals: Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMD

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

AbbVie Inc to Acquire ImmunoGen

Carlisle Companies Inc and Arcturus Therapeutics Granted Approval in Japan of a Novel Self-Amplifying mRNA Vaccine for COVID-19

Immunovant Inc: Positive IMVT-1402 Results that Would Confirm Best-in-Class Potential in Treating Autoimmune Diseases

Anavex Announced US Patent Office Granted a Patent No. 11,813.242 Entitled A273 a Therapeutic for Insomnia, Anxiety and Agitation

For Migraine Patients and People Interested in New Migraine Results, AbbVie Inc is Published in The Lancet.

Vertex Pharmaceuticals and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY

About the FDA Approval of Eli Lilly’s Product Zepbound for Obesity

Current News From Three Selected Biotech Firms

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association Scientific Sessions 2023

More Good News for Neurocrine Biosciences

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Good News for CRISPR Therapeutics and Vertex Pharmaceuticals